Hovid issues recall for Ternolol 50 hypertension tablets


Moody's outlook on the Korean banking system has been negative since May 2016.

KUALA LUMPUR: Hovid Bhd has announced a recall for Ternolol 50mg film-coated tablets manufactured under batch number BG04645 bearing manufacturing date April 2016 for the Malaysian market.

In a filing to Bursa Malaysia on Friday, Hovid said the batch for recall contained boxes labelled as Ternolol 50, however, some of the blisters stated the product as Ternolol Tab 100mg

The pharmaceutical company said the actual product packed in the boxes was Ternolol 50mg which corresponded to the box label.

The tablets contain active atenolol ingredients which are prescribed for hypertension treatment.

“We do not view such errors lightly and is presently investigating the matter. We will implement the required preventive measures to ensure there are no re-occurrence and are working closely with the National Pharmaceutical Regulatory Agency (NPRA),” said Hovid.

It added that the cost of the batch and revenue generated was less than RM25,000.

On Thursday, the NPRA said it had ordered Hovid to withdraw batch BG04645 Ternolol 50 film-coated tablets.

The agency said patients should return the medicine to clinics, pharmacies or health clinics and ask for advice from medical practitioners and undergo examination if necessary. - Bernama

Get 20% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 11.12/month

Billed as RM 11.12 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 9.87/month

Billed as RM 118.40 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Covered but still exposed
Auction market rising
Why some homes rot faster
Perlis Inland Port to contribute to US$30bil Malaysia-Thailand trade target
Hormuz gloom for European stocks
Asia-Pacific debt markets gain traction
Shifting to a lower gear
Sobering times for alcohol industry
Climate tech latest investment play
Oriental Kopi’s quick profit dip highlights challenges in F&B sector

Others Also Read